CN101141972A - Gastrointestinal drug composition - Google Patents
Gastrointestinal drug composition Download PDFInfo
- Publication number
- CN101141972A CN101141972A CNA2006800087386A CN200680008738A CN101141972A CN 101141972 A CN101141972 A CN 101141972A CN A2006800087386 A CNA2006800087386 A CN A2006800087386A CN 200680008738 A CN200680008738 A CN 200680008738A CN 101141972 A CN101141972 A CN 101141972A
- Authority
- CN
- China
- Prior art keywords
- drug composition
- gastrointestinal drug
- gastrointestinal
- mmsc
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004083 gastrointestinal agent Substances 0.000 title claims abstract description 34
- 229940127227 gastrointestinal drug Drugs 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 210000002784 stomach Anatomy 0.000 claims abstract description 12
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 10
- 230000008673 vomiting Effects 0.000 claims abstract description 10
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 9
- 206010047700 Vomiting Diseases 0.000 claims abstract description 5
- 230000029087 digestion Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 9
- 230000003187 abdominal effect Effects 0.000 claims description 8
- 238000005660 chlorination reaction Methods 0.000 claims description 6
- 210000004916 vomit Anatomy 0.000 claims description 5
- 230000036186 satiety Effects 0.000 claims description 3
- 235000019627 satiety Nutrition 0.000 claims description 3
- 230000007659 motor function Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000002496 gastric effect Effects 0.000 abstract description 3
- MYGVPKMVGSXPCQ-JEDNCBNOSA-N Methylmethionine sulfonium salt Chemical compound [Cl-].C[S+](C)CC[C@H](N)C(O)=O MYGVPKMVGSXPCQ-JEDNCBNOSA-N 0.000 abstract description 2
- 229940125695 gastrointestinal agent Drugs 0.000 abstract 2
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 206010059186 Early satiety Diseases 0.000 abstract 1
- 206010015137 Eructation Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 3
- 239000003866 digestant Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 241000132011 Atractylodes lancea Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- -1 stomachic Substances 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000132003 Atractylis Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a gastrointestinal agent having a significantly enhanced effect of a gastrointestinal drug. A gastrointestinal agent composition comprising methylmethionine sulfoniumchloride and a herb Atractylodis Lanceae Rhizoma, particularly for the prevention of eructation, nausea or vomiting or the alleviation of early satiety, feeling of heavy stomach, dyspepsia, gastric or abdominal bloating or anorexia.
Description
Technical field
The present invention relates to a kind of contain the chlorination methylthio-aminoacids (methylmethionine sulfoniumchloride, MMSC) and the remarkable enhanced gastrointestinal drug composition of effect of Rhizoma Atractylodis.
Background technology
Usually, gastrointestinal drug is meant the effect with symptoms such as alleviating feed satiety, heartburn, food stagnation, stomachache, disgusting, vomiting, for making gastrointestinal keep fit state or the widely used medicine of the state of getting well, be subdivided into digestant, stomachic, antacid, compound gastrointestinal drug, gastrointestinal antispasmodic analgesic etc.
Because chlorination methylthio-aminoacids (MMSC) has repair to the gastric mucosa of damage, therefore as gastrointestinal drug particularly compound gastrointestinal drug a kind of composition and be widely used.In addition, Rhizoma Atractylodis are Atractylodes lancea (Thunb.) DC. (Atractylodes lancea De Candolle) or Atractylis chinensis (Atractylodes chinensisKoidzumi) rhizome, just be familiar with by people as crude drug from ancient times, main as being good for the stomach (non-patent literatures 1) such as digestant or antidiarrheal drug for controlling intestinal function.But up to the present the medical composition that both are cooperated particularly gastrointestinal drug does not also exist.
Non-patent literature corrected Pharmacopeia of Japan in 1: the 14 and separates monologue story-telling with gestures, calendar year 2001, D-674～677 page (the Japanese original text: the 14th corrects Pharmacopeia of Japan explains orally Books, calendar year 2001, D-674～677 Page)
Summary of the invention
The object of the present invention is to provide a kind of and original gastrointestinal drug to compare the novel gastroenteritic drug composition that effectiveness significantly improves.
Discoveries such as the inventor, to be used as the be good for the stomach Rhizoma Atractylodis of digestant or antidiarrheal drug for controlling intestinal function of the known chlorination methylthio-aminoacids of gastric mucosa repairing agent (MMSC) and known conduct, show significant digestion promoting road dynamic action, the result as the inhibition belch of gastrointestinal drug, disgusting, feel sick, vomit or remove effects such as uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or inappetence and significantly improve, thereby finished the present invention.
That is: the invention provides the gastrointestinal drug composition of a kind of MMSC of containing and Rhizoma Atractylodis.In addition, the invention still further relates to a kind of be used to suppress belch, disgusting, feel sick, vomit or remove uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or gastrointestinal drug composition inappetence, that contain MMSC and Rhizoma Atractylodis.
Gastrointestinal drug composition of the present invention, the collaborative digestion promoting road dynamic action that improves that all is beyond one's reach when using MMSC or Rhizoma Atractylodis separately respectively reach inhibition belch that following effect: MMSC has, disgusting, feel sick, vomit or remove effects such as uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or inappetence and be significantly improved.
The specific embodiment
MMSC is the medicine that nineteen fifty-nine begins to go on the market, mainly as gastric mucosa repairing agent or improve the liver function of chronic hepatopathy.But, MMSC and Rhizoma Atractylodis are also used the significant digestion promoting of demonstration road dynamic action, the result compares during with independent use MMSC, the effect that suppresses the effect of belch, disgusting, nauseating, vomiting or remove uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or inappetence is significantly improved, and does not report so far about this point.
In addition, about Rhizoma Atractylodis, though the known effect (non-patent literature 1) that the motion of facilitating digestion road is arranged, but, by with MMSC and usefulness, this effect obtains collaborative the enhancing, the result obtains collaborative the raising as the effect of the gastrointestinal drug composition that contains MMSC and Rhizoma Atractylodis, does not report so far about this point.
MMSC and Rhizoma Atractylodis and the usefulness of the present invention by will not be used in the past provides a kind of gastrointestinal drug composition that can't reach the collaborative effect that improves when using separately respectively that has.
Gastrointestinal drug composition of the present invention has the digestion promoting road dynamic action of representing with the intestinal transfer rate as shown in following embodiment.Confirm that its effect is significantly higher than the total of the effect when using MMSC, Rhizoma Atractylodis separately respectively, produces the motion of synergism facilitating digestion road.
The present invention is not limited to following inference: the present invention is by this collaborative digestion promoting road dynamic action, compare during with independent use MMSC or Rhizoma Atractylodis, can significantly improve and be detained symptoms, particularly these symptoms that cause by insobriety or feed satiety such as the belch cause, disgusting, vomiting, uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension and inappetence because of intestinal contents.In addition, by collaborative digestion promoting road dynamic action, also can remove intestinal contents and be detained, more strongly facilitating digestion.
The MMSC that uses among the present invention for example can use the damp creek of rice to manage the commercially available product of pharmaceutical industries (Co., Ltd.) (Japanese original text: Mi swamp creek reason pharmaceutical industries (strain)), also can use the synthetic MMSC of method according to the public clear 36-13209 communique record of spy.In addition, Rhizoma Atractylodis can use the product that circulates extensively use as the crude drug composition.
About the match ratio and the synergism thereof of MMSC and Rhizoma Atractylodis, by weight MMSC: Rhizoma Atractylodis (in crude drug in whole) are 9 parts: 8 parts～3 parts: 500 parts, particularly 1 part: 2 parts～1 part: in the time of 5 parts, can bring into play more fully and with the synergy of generation.In addition, the use level in the compositions of MMSC and Rhizoma Atractylodis can determine to satisfy the amount of above-mentioned match ratio respectively according to the scope of the amount that can cooperate as gastrointestinal drug composition separately.
In addition, gastrointestinal drug composition of the present invention, except MMSC and Rhizoma Atractylodis, the form that also can contain the medical composition of pharmaceutically acceptable carrier and other medical components, excipient, binding agent, disintegrating agent, lubricant, coloring agent, correctives etc. is used.
Excipient for example has lactose, starch based, crystalline cellulose, sucrose, mannitol, light silicon dioxide etc.Binding agent for example has hydroxypropyl emthylcellulose, hydroxypropyl cellulose, gelatin, alphalysed starch, polyvinylpyrrolidone, polyvinyl alcohol, pulullan polysaccharide etc.Disintegrating agent for example has carboxymethyl cellulose, carboxymethylcellulose calcium, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, corn starch, low-substituted hydroxypropyl cellulose etc.Lubricant for example has magnesium stearate, Talcum etc.Coloring agent for example has tar colorant, iron sesquioxide etc.Correctives for example has Folium Stevlae Rebaudianae, aspartame, spice etc.
Gastrointestinal drug composition of the present invention can be prepared into dosage forms such as powder, granule, tablet, chewable tablet, thin membrane coated tablet, coated tablet, oral liquid, soft capsule, hard capsule, gel and use according to purpose.Special preferred for preparation becomes the dosage form of powder, granule, tablet, thin membrane coated tablet to use.
In addition; the gastrointestinal drug composition that contains MMSC and Rhizoma Atractylodis is used for the dosage of man-hour; with factors such as dosage form, disease degree, patient ages dependence is arranged; usually the adult gives MMSC30～3000mg/ days basically; preferred especially 100～225mg/ days; cooperate this dosage, can determine the dosage of Rhizoma Atractylodis.
Be described more specifically the present invention below by embodiment, but these examples are not limitation of the present invention.
Embodiment 1
Test the previous day jejunitas 5 age in week ddY be the chlorination methylthio-aminoacids that suspends in oral 0.5% methylcellulose of male mice (to call MC in the following text) (1000mg/kg, to call M in the following text), Rhizoma Atractylodis powdered extract S (300mg/kg, be equivalent to crude drug in whole 3000mg/kg, to call S in the following text) and their mixture (to call M+S in the following text), after 15 minutes, Orally active charcoal end suspension.Animal is put to death in the cervical vertebra dislocation after 30 minutes again, extracts the intestinal tube of pyloric part to ileocecus.The intestinal that is tried thing is carried function to use from the displacement at the charcoal end of pyloric part to represent divided by the intestinal transfer rate that the total length of intestinal tube obtains.
Result of the test is as shown in table 1.
Table 1
| Group | Intestinal transfer rate (%) (meansigma methods ± SE) | Ratio 1) |
| Matched group M S M+S | 48.5±3.5 69.0±1.1 53.0±3.1 76.2±2.8 | 1.00 1.42 1.09 1.57 |
M: chlorination methylthio-aminoacids
S: Rhizoma Atractylodis powdered extract S
1)The intestinal transfer rate of matched group is the ratio of 1 o'clock intestinal transfer rate
About the intestinal transfer rate, the matched group that gives MC is 48.5%, M organizes is 69.0%, S organizes is 53.0%, M+S organizes is 76.2%.The intestinal transfer rate of matched group is that the ratio of intestinal transfer rate of 1 o'clock M+S group is 1.57, and bigger than the product 1.55 (1.42 * 1.09) of single medicine group, judging has synergy.Hence one can see that, gastrointestinal drug composition facilitating digestion of the present invention road motor function, the result suppress belch, disgusting, feel sick, vomit or remove effects such as uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or inappetence and significantly strengthen, this gastrointestinal drug composition is very useful.
Embodiment 2
Excipient uses lactose, after wet granulation method preparation routinely contains the granule of MMSC, presses the well-established law compression molding, prepares every tablet A that contains 25mg MMSC.In addition, use with quadrat method and prepare every tablet B that contains 25mg MMSC and 12mg (in crude drug in whole) Rhizoma Atractylodis.
There is 20～50 years old male volunteers of stationarity abdominal discomfort in 10 stomach main suits of random choose, are divided into 2 groups (A group and B groups), every group each 5.A group is taken tablet A, and the B group is taken tablet B, whenever after the meal each 2, took continuously respectively 3 days, with the questionnaire survey form answer take before in after the variation of malaise symptoms.The result is as shown in table 2.
Can confirm by table 2: take the B group of gastrointestinal drug composition of the present invention, the effect that the abdominal discomfort symptom is significantly improved.
Table 2
Claims (5)
1. gastrointestinal drug composition that contains chlorination methylthio-aminoacids and Rhizoma Atractylodis.
2. gastrointestinal drug composition as claimed in claim 1, wherein said gastrointestinal drug composition be used to suppress belch, disgusting, feel sick, vomit or remove uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or inappetence.
3. gastrointestinal drug composition as claimed in claim 2, wherein said belch, disgusting, nauseating, vomiting, uncomfortable in chest, food stagnation, dyspepsia, stomach abdominal part distension or inappetence are caused by insobriety or feed satiety.
4. gastrointestinal drug composition as claimed in claim 1, wherein said gastrointestinal drug composition is used for facilitating digestion.
5. gastrointestinal drug composition as claimed in claim 1, wherein said gastrointestinal drug composition are used for facilitating digestion road motor function.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP156667/2005 | 2005-05-30 | ||
| JP2005156667 | 2005-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101141972A true CN101141972A (en) | 2008-03-12 |
Family
ID=37481410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800087386A Pending CN101141972A (en) | 2005-05-30 | 2006-05-17 | Gastrointestinal drug composition |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5070047B2 (en) |
| KR (1) | KR101254511B1 (en) |
| CN (1) | CN101141972A (en) |
| TW (1) | TWI430807B (en) |
| WO (1) | WO2006129479A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012527451A (en) * | 2009-05-22 | 2012-11-08 | エスケー ケミカルズ カンパニー リミテッド | Composition for preventing or treating irritable bowel syndrome |
| KR20130066874A (en) * | 2011-12-13 | 2013-06-21 | 에스케이케미칼주식회사 | Compound for preventing or treating irritable bowel syndrome and composition containing the same |
-
2006
- 2006-05-05 TW TW095116012A patent/TWI430807B/en active
- 2006-05-17 WO PCT/JP2006/309791 patent/WO2006129479A1/en active Application Filing
- 2006-05-17 CN CNA2006800087386A patent/CN101141972A/en active Pending
- 2006-05-17 KR KR1020077022751A patent/KR101254511B1/en active IP Right Grant
- 2006-05-17 JP JP2007518901A patent/JP5070047B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI430807B (en) | 2014-03-21 |
| WO2006129479A1 (en) | 2006-12-07 |
| JPWO2006129479A1 (en) | 2008-12-25 |
| TW200716160A (en) | 2007-05-01 |
| JP5070047B2 (en) | 2012-11-07 |
| KR20080026084A (en) | 2008-03-24 |
| KR101254511B1 (en) | 2013-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041280B (en) | Compound traditional Chinese medicine for diminishing inflammation, checking diarrhea and relieving pain | |
| CN111481648B (en) | Traditional Chinese medicine composition for tonifying spleen and nourishing stomach and traditional Chinese medicine preparation | |
| CN102696948B (en) | Constipation improving food and preparation method thereof | |
| JP6864970B2 (en) | Gastrointestinal drug composition | |
| CN101524520A (en) | Chinese medicinal composition for resisting chronic gastritis and preparation method thereof | |
| CN104173906A (en) | Traditional Chinese medicine composition for treating gastrectasia | |
| CN102125660A (en) | Traditional Chinese medicine sustained-release micro granules stomach and intestine partner for protecting and strengthening functions of stomach and intestine | |
| CN107095995B (en) | A pharmaceutical composition for treating gastritis and gastric ulcer, and its preparation method | |
| CN103977206B (en) | Improve Chinese medicine preparation and the production method thereof of gastrointestinal disturbances systemic-function | |
| CN101141972A (en) | Gastrointestinal drug composition | |
| CN101530562A (en) | Pharmaceutical composition for treating female kidney-yin deficiency | |
| CN112755168B (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by helicobacter pylori and preparation method and application thereof | |
| CN101141954A (en) | Gastrointestinal motor activation regulator | |
| CN103877483A (en) | Traditional Chinese medicine for treating chronic gastritis and preparation method thereof | |
| CN104645294B (en) | It is a kind of to treat Chinese medicine composition of baby diarrhea and its preparation method and application | |
| CN106620474B (en) | Stomach-nourishing health-care medicine and preparation method thereof | |
| CN104784400A (en) | Stomach-invigorating and distension-relieving tablet and preparation method thereof | |
| CN105148151A (en) | Medicine for treating spleen and stomach deficiency-cold type reflux esophagitis and preparation method | |
| CN101569655B (en) | Radix astragali gastric floating tablet suitable for treating chronic superficial gastritis | |
| CN101607061A (en) | A kind of drug regimen of protecting gastric mucosa and preparation method thereof | |
| CN1943749B (en) | A Chinese traditional medicinal composition for treatment of Child's feeblemindedness of and its preparation method | |
| AU2021103634A4 (en) | Fast dissolving tablets for restoring immunity | |
| CN101607052A (en) | A kind of drug regimen for the treatment of chronic atrophic gastritis and preparation method thereof | |
| CN102139016A (en) | Medlar floating tablet for treating chronic gastritis and preparation method thereof | |
| CN101537122A (en) | Chinese traditional medicine composition for curing constipation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1115806 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080312 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1115806 Country of ref document: HK |